Clinical trials: Benign Prostate Hypertrophy(BPH)
Prostatic Hyperplasia, Benign, Erectile Dysfunction
Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia
- Trial name
- AUSTRÁLIA (NCT06264414)
- Testing
- DTT106, Dutasteride-Tamsulosin
- Where
- Brazil
- Volunteers
- 262 people
- Sponsor
- EMS
BPH (Benign Prostatic Hyperplasia)
Impact of Kegel Exercise on Patient Outcomes Post TURP
how kegel exercise will improve patient outcomes by reducing post TURP LUTs , improve patient performance status and improve patient self esteem
- Trial name
- NCT06948604
- Testing
- Exercise
- Volunteers
- 92 people
- Sponsor
- Assiut University
Benign Prostatic Hyperplasia
Study on Water Vapor Thermal Therapy
The goal of this observational study is to learn about the efficacy of Rezum water vapor thermal therapy in benign prostatic hyperplasia patients.
- Trial name
- NCT06656689
- Testing
- Rezum (water vapor thermal therapy)
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Saint Vincent's Hospital, Korea
Benign Prostatic Hyperplasia
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
To compare between efficacy of phosphodiesterase5 inhibitors (tadalafil 5 mg) and Alpha Blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia.
- Trial name
- NCT05236634
- Testing
- Phosphodiesterase 5 Inhibitors, Alpha Blockers, Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
- Volunteers
- 120 people
- Sponsor
- Assiut University
Acute Urinary Retention, Benign Prostate Hypertrophy(BPH)
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk…
- Trial name
- NCT07733934
- Testing
- Teverelix DP
- Volunteers
- 126 people
- Sponsor
- Antev Ltd.
Benign Prostatic Hyperplasia, Incontinence
The Risk Factor and Outcome of Transient Incontinence After Prostate Enucleation Surgery
Lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) are the most common urological problem among men. monopolar transurethral resection of the prostate (TURP), in which the enlarged prostate tissue is…
- Trial name
- PPI (NCT05116592)
- Where
- Taiwan
- Volunteers
- 330 people
- Sponsor
- National Taiwan University Hospital
Benign Prostatic Hyperplasia
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
A randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of YY-201 in comparison to Dutasteride and Tadalafil administered in healthy male volunteers
- Trial name
- NCT03240939
- Testing
- Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with…
- Trial name
- NCT00409357
- Testing
- SL77.0499-10 (alfuzosin hydrochloride)
- Where
- Japan
- Volunteers
- 473 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).
- Trial name
- TRIUMPH-1 (NCT00889707)
- Testing
- PRX302
- Where
- 9 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
Middle Lobe Only Laser Vaporization or Total Prostate Vaporization of the Prostate, Prospective Cohort Study
The investigator aims to prospectively investigate the efficacy and durability of the middle lobe only versus traditional complete photoselective greenlight vaporization of the prostate in patients with prominent middle lobe.
- Trial name
- NCT04529369
- Testing
- Middle lobe only Photoselective vaporization of the prostate (PVP), Complete PVP
- Volunteers
- 280 people
- Sponsor
- Jewish General Hospital
Male, Ultrasonography
Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia
To compare safely and efficacy of intraprostatic injection of botulinum toxin A versus ethanol for treatment of benign prostatic hyperplasia (BPH).
- Conditions
- Male, Ultrasonography, Botulinum Toxins, Type A, Injection; Complications, Infection
- Trial name
- NCT03385161
- Testing
- Botulinum toxin A, Ethanol
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
- Trial name
- NCT07632742
- Testing
- Magneto 150 holmium laser, Moses 2.0 holmium laser
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Benign Prostatic Hyperplasia
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00918983
- Testing
- NX-1207
- Where
- 41 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Prostate Cancer
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
This study will investigate the efficacy of Degarelix, a Luteinizing Hormone Releasing Hormone (LHRH) antagonist, to reduce prostate volume prior to permanent seed prostate brachytherapy.
- Trial name
- NCT01446991
- Testing
- Degarelix
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency